The decrease of $13.4 million to the cash balance at the end of the fourth quarter includes Harpoon’s follow-on financing that closed on Januresulting in net proceeds of approximately $107.6 million, less cash spend during the twelve months on operating expenses. Harpoon ended the fourth quarter of 2021 with $136.6 million in cash, cash equivalents, and marketable securities compared to $150.0 million as of December 31, 2020.
#HARPOON FEST 2021 FULL#
In November 2021, preclinical data supporting Harpoon’s proprietary TriTAC-XR T cell engager platform was highlighted in a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, demonstrating that the platform could mitigate toxicities such as cytokine release syndrome.įourth Quarter and Full Year 2021 Financial Results These interim data demonstrated clinical activity at higher dose levels, strong target engagement, and a manageable safety profile. An overall response rate of 63% and a disease control rate of 88% in the HPN217 2150 µg/week cohort was observed. In December 2021, at the 63rd American Society of Hematology Annual Meeting and Exposition, the company reported interim data from the Phase 1/2 study of HPN217, a half-life extended TriTAC targeting B cell maturation antigen (BCMA) for the treatment of relapsed, refractory multiple myeloma. Harpoon to select an RP2D and initiate dose expansion cohort by mid-2022.Ĭomplete dose escalation by year-end 2022.Īdvancing Harpoon’s first ProTriTAC molecule, with an IND submission anticipated by year-end 2022.
#HARPOON FEST 2021 TRIAL#
Harpoon to continue dose escalation to determine RP2D by year-end 2022.Ĭompelling initial clinical activity observed in escalation phase of ongoing trial In the ongoing Phase 1/2 trial for HPN328, 3 out of 4 patients with small cell lung cancer in the two highest dose cohorts experienced target lesion (TL) reduction, with one patient achieving a confirmed partial response with a 53% TL reduction.
#HARPOON FEST 2021 UPDATE#
In December 2021 Harpoon provided a pipeline update and in January 2022 issued milestone updates to highlight its TriTAC clinical progress, as well as its platform technologies and next clinical candidate in development: In March 2022, Harpoon announced Fast Track designation for HPN217 in relapsed, refractory multiple myeloma
In March 2022, Harpoon announced Orphan Drug designation for HPN328 in small cell lung cancer We thank the patients, investigators and our employees for supporting this clinical study,” said Natalie Sacks, M.D., Chief Medical Officer of Harpoon Therapeutics.įourth Quarter 2021 and Recent Business Highlights and Upcoming Milestones “We are committed to ongoing support of those patients who remain on our HPN424 trial. “Additionally, we have conducted a careful and thorough analysis of our HPN424 data, including our clinical results to date, and based on those data we have made the decision to discontinue the HPN424 dose escalation study.” We are focusing our resources on portfolio programs that show promising activity, including HPN328 and HPN217, while we advance new candidates into the clinic from our technology platforms,” said Julie Eastland, President and Chief Executive Officer of Harpoon Therapeutics.
“We look forward to additional clinical advancements in the year ahead. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended Decemand provided a corporate update. SOUTH SAN FRANCISCO, Calif., Ma(GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc.
0 kommentar(er)
